The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to ...

A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers ...

In 2025, the market was valued at $2.7 billion, projected to reach $2.92 billion in 2026, with a CAGR of 8.1%. This ...

A new CAR-T cell therapy has shown promising early results against glioblastoma, a highly aggressive brain cancer. In a phase ...

Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab ...

In April 2022, my mother-in-law, Karla, went for a routine physical therapy visit for carpal tunnel pain. The clinic was full and nearly turned her away. Only after she insisted that something felt ...

Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...

Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...